OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Daniel J. Gerritzen Sells 5,310 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the transaction, the general counsel now directly owns 110,767 shares of the company’s stock, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS opened at $25.42 on Wednesday. The company has a market cap of $617.38 million, a PE ratio of -20.67 and a beta of 1.22. OrthoPediatrics Corp. has a 12 month low of $21.02 and a 12 month high of $35.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The company has a 50-day simple moving average of $24.79 and a 200-day simple moving average of $25.53.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. The company had revenue of $52.67 million during the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same quarter in the previous year, the business earned ($0.23) EPS. On average, equities analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in OrthoPediatrics in the 3rd quarter valued at about $25,000. R Squared Ltd purchased a new stake in OrthoPediatrics during the fourth quarter valued at about $48,000. KLP Kapitalforvaltning AS purchased a new stake in OrthoPediatrics during the fourth quarter valued at about $79,000. BNP Paribas Financial Markets grew its position in OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after acquiring an additional 1,929 shares during the period. Finally, Quantbot Technologies LP grew its position in OrthoPediatrics by 42.2% during the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after acquiring an additional 1,712 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on KIDS shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th. Stifel Nicolaus reduced their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Finally, Truist Financial cut their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.